前立腺肥大症に伴う排尿障害に対するシロドシンの服用後早期効果に関する多施設共同臨床研究(SELECTIVITY) : Silodosin Early Effectiveness and Safety Multi Center Trial in Yokohama

Autor: Ogawa, Takehiko, Uemura, Hiroji, Sano, Futoshi, Hoshino, Kouji, Kita, Kaoru, Hayashi, Narihiko, Kagota, Masayo, Murakami, Takayuki, Makiyama, Kazuhide, Miyoshii, Yasuhide, Nakaigawa, Noboru, Yao, Masahiro, Shimura, Hidetoshi, Furuhata, Akihiko, Fujikawa, Naoya, Shioi, Koichi, Ueki, Teiichiro, Hara, Yoshinori, Saitou, Kiyoshi, Kawakami, Satoshi, Satomi, Yoshiaki, Hattori, Yusuke, Teranishi, Junichi, Kondo, Keiichi, Kishida, Takeshi, Saito, Kazuo, Noguchi, Kazumi, Fujii, Hiroshi, Yamaguchi, Toyoaki, Kinoshita, Yuzo, Nomura, Sakae, Yoshida, Minoru, Sakai, Naoki, Terao, Hideyuki, Matsumoto, Tatsuya, Umemoto, Susumu, Ogo, Yoshiharu, Kobayashi, Kazuki, Noguchi, Sumio, Asakura, Tomoyuki, Kohdaira, Teruo, Iguchi, Kozue, Izumi, Koji, Hirano, Masami, Kanno, Hitomi, Takahashi, Toshihiro, Nukui, Fumihiko, Mokuo, Yasuhiro, Muraoka, Kentaro, Osada, Yutaka, Funahashi, Makoto, Kitami, Kazuo, Sugiura, Shimpei, Ohta, Junichi, Miura, Takeshi, Ishibashi, Yoshio, Masuda, Mitsunobu, Komiya, Atsushi, Suwa, Yutaka, Hashiba, Takafumi, Mitaka, Kunihisa, Kobayashi, Masataka, Ohsaka, Kimito, Takano, Tetsuzo, Tsuchiya, Futoshi, Iwasaki, Akira, Yamashita, Yuzo, Matsuzaki, Junichi, Kubota, Yoshinobu
Jazyk: japonština
Rok vydání: 2008
Předmět:
Zdroj: 泌尿器科紀要. 54(12):757-764
ISSN: 0018-1994
Popis: Silodosin (URIEF), a new so-called 3rd generation alpha-1 blocker, is widely expected to be effective and useful for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), due to its high specificity to alpha-1A receptor. We evaluated the efficacy of Silodosin, on 187 males 50 years old or over with the diagnosis of BPH. Silodosin significantly improved the International Prostate Symptom Score (IPSS) and quality of life (QOL) score from the day after administration was started. Among 166 patients whose data were available for the analysis of efficacy of Silodosin, 77.5% showed apparent subjective improvement. Eighty three patients, who had been taking another alpha-1 blocker but without satisfactory effects, showed almost the same improvements in IPSS and QOL score after switching to Silodosin as the remaining 83 patients who had no preceding treatment with an alpha-1 blocker. The improvements were not only in voiding symptoms but also in storage symptoms. The patients, who had serious storage symptoms, responded rather well to Silodosin and showed significant improvement. Taken together, Silodosin showed a quick effect for improving subjective symptoms and QOL, and was found to be useful for the management of LUTS with BPH.
2006年11月～2007年10月の前立腺肥大症166例(年齢69.9±6.4歳)を対象にシロドシン服用後超早期での有効性を検討した。シロドシン8mg/日を2週間処方し、排尿症状日誌に国際前立腺症状スコア(IPSS)、QOLスコア、BPH impact indexを記入してもらい、効果判定を行った。その結果、IPSSは服用開始後1、2、3日目と低下し、いずれの観察日も開始時と有意差を認め、14日目は更に低下した。QOLスコアも同様に有意な低下を示し、IPSSとQOLスコアの相関関係を認めた。また、α1遮断薬から切り替えた患者とα1遮断薬を初めて服用した患者との比較では、両群とも服用後1日目からIPSSは有意に低下して14日目まで低下し続け、2群間に有意差は認めなかった。14日目の治療判定ではExcellent 25例、Well 99例、Poor 36例であり、Poor例はいずれの観察日もIPSSの低下を認めなかった。IPSSのサブスコアの排尿、蓄尿症状の変化量は服用後1日目より有意に改善し、蓄尿症状重症例においても同様に1日目より有意に改善効果を認めた。副作用は187例中23例(12.3%)に認め、下痢が11例5.9%と最も多く、重篤な副作用は認めず、高齢により高くなる傾向は認めなかった。以上よりシロドシンの早期からの効果が判明し、無効な症例では早い時点で適した薬剤・治療法の提供が可能になると考えた。
Databáze: OpenAIRE
Externí odkaz: